Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Treating Ebola And Beyond: Spotlight On Novel Hemopurifier

Executive Summary

Aethlon Medical’s Hemopurifier device was successfully used in Germany to treat a Ugandan physician with Ebola, and now the company is preparing to launch its first human clinical studies in the US. Aethlon hopes this novel device will provide a first-in-class broad-spectrum treatment countermeasure against pandemic threats such as Ebola and chronic viral pathogens.

You may also be interested in...



WHO Launches Initiatives For Ebola POC Tests

The World Health Organization has initiated a rapid review process and is providing early test validation materials to encourage more manufacturers to quickly develop rapid, point-of-care Ebola tests. Meanwhile, Aethlon Medical is providing its bio-filtration device to treat blood of Ebola patients.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035726

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel